IL2 and neoplasm: We hypothesized that three key parameters may impact the efficacy of EIIIB-targeted small IL-2 immunocytokines: (1) nanobody affinity to EIIIB, (2) abundance of EIIIB at the tumor site, and (3) route of administration.